Rare deafness therapy’s hearing gains last years

People born with one rare form of inherited deafness can now register sounds that once produced no measurable hearing response at all. In a trial across eight hospitals in China, 38 of 42 participants showed that change after a single dose of gene therapy, according to results published in Nature in April (Fudan University). Because the therapy supplies a working copy of one specific gene, it can only help this small group. Within that group, though, the change in measured hearing was large.

What the hearing test actually measures

The trial measured hearing with a test that plays sounds at different volumes. It records the quietest sound that triggers a measurable response along the hearing pathway, and that level is called the threshold. Picture turning a radio up from silence. The threshold is the point on the dial where you first catch anything, so a lower number means softer sounds are getting through.

Before treatment, the participants' average threshold sat above 97 on the specialised scale this test uses, and in the patients followed longest, two and a half years after the dose, it had fallen to 42 (Nature). In plain terms, the ear went from reacting only to very loud sounds, if at all, to reacting to much quieter ones.

That longest follow-up covers only part of the group, because patients joined the trial at different times. Harvard Medical School's account of the same trial describes the hearing gains as lasting years (Harvard Medical School). The trial was also single-arm. Everyone received the therapy and there was no untreated comparison group, so each patient's results were measured against their own hearing before treatment.

A missing recipe, supplied

Genes work like recipes that cells follow to build proteins, the molecules that do most of the body's work. The OTOF gene carries the recipe for a protein called otoferlin, which the ear needs in order to hear. People with this form of deafness inherit faulty copies of the gene, so their cells have no usable recipe to follow.

The therapy hands those cells a working copy, a bit like slipping a missing page back into a cookbook so the kitchen can finally make the dish. The idea is that the cells can then make otoferlin themselves. The trial judged that idea by its outcome, whether the hearing pathway began responding to sound, and for most participants it did.

The same precision sets the therapy's limits. A treatment that supplies one specific recipe can only help people whose deafness comes from faulty OTOF genes. Finding them means genetic testing, since this form of deafness shares its outward signs with many other causes of hearing loss.

On safety, the researchers reported no dose-limiting toxicity in the early period the trial was designed to check. That means no side effects severe enough to rule out the dose being tested. They did record a serious fall in neutrophils, the white blood cells that act as the body's first responders to infection (Nature).

From hearing sounds to understanding words

A lower threshold shows that softer sounds now register. On its own, it does not show ordinary hearing, and it says nothing direct about understanding speech. Think of a child getting their first pair of glasses. The glasses make letters sharp, but reading is still a skill the child has to learn.

Sound works in a similar way. The brain has to learn to turn a stream of noise into words, and that learning takes time and practice with sound. Patients who regained hearing in this trial did show gradual gains in understanding speech, according to Harvard Medical School. Gradual is the right word, because language develops over months and years rather than at the moment a test registers a response.

That is why the two findings deserve to be read separately. The hearing result is the strong one. It rests on a direct measurement, taken before and after treatment, in a large share of the people who received the dose. The speech result points in the right direction but depends on a slower process that the follow-up is still tracking.

For people with this specific inherited deafness, the trial shows that a single dose of gene therapy can produce substantial gains in measured hearing, and that in the patients followed longest those gains held. Whether they reliably turn into better speech and language is what continued follow-up of these same patients still has to show.